MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.thromres.2025.109402

Медицинская библиотека · Thrombosis research · 2025

Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study.

Kim Ji Yoon, Hwang Taiju, Park Sang Kyu, Yoo Ki-Young, Choi Eun Jin, Kim Soyon, You Chur Woo, Kim Eungsun, Jung Aeran, Park Young-Shil

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

Rurioctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) with an extended half-life versus the parent product. Limited real-world data exist on the treatment of hemophilia A with rurioctocog alfa pegol in South Korea. This postmarketing surveillance study assessed its safety and effectiveness in a real-world setting, according to Korean regulatory requirements.

METHODS

In this prospective, multicenter study (NCT03824522), data were collected from medical records of patients, including children, with hemophilia A receiving rurioctocog alfa pegol as standard clinical practice in South Korea. Safety (adverse events [AEs], adverse drug reactions [ADRs], and unexpected AEs/ADRs) and hemostatic effectiveness were analyzed.

RESULTS

In total, 338 patients were included (mean age [range], 25.0 [1.0-61.0] years; children <12 years, n = 54 [16 %]; all had a history of FVIII treatment). AEs occurred in 20 (5.9 %) patients (unexpected AEs, n = 18 [5.3 %]; ADRs, n = 4 [1.2 %]; unexpected ADRs, n = 2 [0.6 %]; serious AEs, n = 4 [1.2 %]; serious ADRs, n = 0 [0.0 %]). Among children, AEs occurred in 1 (50 %) and 6 (11.5 %) patients aged <2 and ≥2 to <12 years, respectively. No new safety signals were observed. No bleeding events occurred in 239 (76.1 %) patients on prophylaxis. Hemostatic effectiveness was rated by physicians as excellent/good in most patients. Bleeding events were managed with 1-2 infusions. Treatment effectiveness was maintained in children during the study period. No patients developed inhibitor antibodies against rurioctocog alfa pegol.

CONCLUSION

Rurioctocog alfa pegol was effective in children and adults, with no new safety signals; most patients on prophylaxis experienced no bleeds during the study.

Для цитирования: Kim Ji Yoon, Hwang Taiju, Park Sang Kyu, Yoo Ki-Young, Choi Eun Jin, Kim Soyon, You Chur Woo, Kim Eungsun, Jung Aeran, Park Young-Shil. Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study.. Thrombosis research. 2025. DOI: 10.1016/j.thromres.2025.109402.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.